Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist. / Iepsen, Eva W; Zhang, Jinyi; Thomsen, Henrik S.; Hansen, Elizaveta L; Hollensted, Mette; Madsbad, Sten; Hansen, Torben; Holst, Jens J; Holm, Jens-Christian; Torekov, Signe S.

I: Cell Metabolism, Bind 28, Nr. 1, 2018, s. 23-32.e3.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Iepsen, EW, Zhang, J, Thomsen, HS, Hansen, EL, Hollensted, M, Madsbad, S, Hansen, T, Holst, JJ, Holm, J-C & Torekov, SS 2018, 'Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist', Cell Metabolism, bind 28, nr. 1, s. 23-32.e3. https://doi.org/10.1016/j.cmet.2018.05.008

APA

Iepsen, E. W., Zhang, J., Thomsen, H. S., Hansen, E. L., Hollensted, M., Madsbad, S., ... Torekov, S. S. (2018). Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist. Cell Metabolism, 28(1), 23-32.e3. https://doi.org/10.1016/j.cmet.2018.05.008

Vancouver

Iepsen EW, Zhang J, Thomsen HS, Hansen EL, Hollensted M, Madsbad S o.a. Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist. Cell Metabolism. 2018;28(1):23-32.e3. https://doi.org/10.1016/j.cmet.2018.05.008

Author

Iepsen, Eva W ; Zhang, Jinyi ; Thomsen, Henrik S. ; Hansen, Elizaveta L ; Hollensted, Mette ; Madsbad, Sten ; Hansen, Torben ; Holst, Jens J ; Holm, Jens-Christian ; Torekov, Signe S. / Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist. I: Cell Metabolism. 2018 ; Bind 28, Nr. 1. s. 23-32.e3.

Bibtex

@article{13da1155e04d4ca8b247effd7f585f46,
title = "Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist",
abstract = "Pathogenic mutations in the appetite-regulating melanocortin-4 receptor (MC4R) represent the most common cause of monogenic obesity with limited treatment options. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) cause weight loss by reducing appetite. We assessed the effect of the GLP-1 RA liraglutide 3.0 mg for 16 weeks in 14 obese individuals with pathogenic MC4R mutations (BMI 37.5 ± 6.8) and 28 matched control participants without MC4R mutation (BMI 36.8 ± 4.8). Liraglutide decreased body weight by 6.8 kg ± 1.8 kg in individuals with pathogenic MC4R mutations and by 6.1 kg ± 1.2 kg in control participants. Total body fat, waist circumference, and fasting and postprandial glucose concentrations similarly decreased in both groups. Thus, liraglutide induced an equal, clinically significant weight loss of 6{\%} in both groups, indicating that the appetite-reducing effect of liraglutide is preserved in MC4R causal obesity and that liraglutide acts independently of the MC4R pathway. Thus, liraglutide could be an effective treatment of the most common form of monogenic obesity.",
author = "Iepsen, {Eva W} and Jinyi Zhang and Thomsen, {Henrik S.} and Hansen, {Elizaveta L} and Mette Hollensted and Sten Madsbad and Torben Hansen and Holst, {Jens J} and Jens-Christian Holm and Torekov, {Signe S}",
note = "Copyright {\circledC} 2018 Elsevier Inc. All rights reserved.",
year = "2018",
doi = "10.1016/j.cmet.2018.05.008",
language = "English",
volume = "28",
pages = "23--32.e3",
journal = "Cell Metabolism",
issn = "1550-4131",
publisher = "Cell Press",
number = "1",

}

RIS

TY - JOUR

T1 - Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist

AU - Iepsen, Eva W

AU - Zhang, Jinyi

AU - Thomsen, Henrik S.

AU - Hansen, Elizaveta L

AU - Hollensted, Mette

AU - Madsbad, Sten

AU - Hansen, Torben

AU - Holst, Jens J

AU - Holm, Jens-Christian

AU - Torekov, Signe S

N1 - Copyright © 2018 Elsevier Inc. All rights reserved.

PY - 2018

Y1 - 2018

N2 - Pathogenic mutations in the appetite-regulating melanocortin-4 receptor (MC4R) represent the most common cause of monogenic obesity with limited treatment options. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) cause weight loss by reducing appetite. We assessed the effect of the GLP-1 RA liraglutide 3.0 mg for 16 weeks in 14 obese individuals with pathogenic MC4R mutations (BMI 37.5 ± 6.8) and 28 matched control participants without MC4R mutation (BMI 36.8 ± 4.8). Liraglutide decreased body weight by 6.8 kg ± 1.8 kg in individuals with pathogenic MC4R mutations and by 6.1 kg ± 1.2 kg in control participants. Total body fat, waist circumference, and fasting and postprandial glucose concentrations similarly decreased in both groups. Thus, liraglutide induced an equal, clinically significant weight loss of 6% in both groups, indicating that the appetite-reducing effect of liraglutide is preserved in MC4R causal obesity and that liraglutide acts independently of the MC4R pathway. Thus, liraglutide could be an effective treatment of the most common form of monogenic obesity.

AB - Pathogenic mutations in the appetite-regulating melanocortin-4 receptor (MC4R) represent the most common cause of monogenic obesity with limited treatment options. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) cause weight loss by reducing appetite. We assessed the effect of the GLP-1 RA liraglutide 3.0 mg for 16 weeks in 14 obese individuals with pathogenic MC4R mutations (BMI 37.5 ± 6.8) and 28 matched control participants without MC4R mutation (BMI 36.8 ± 4.8). Liraglutide decreased body weight by 6.8 kg ± 1.8 kg in individuals with pathogenic MC4R mutations and by 6.1 kg ± 1.2 kg in control participants. Total body fat, waist circumference, and fasting and postprandial glucose concentrations similarly decreased in both groups. Thus, liraglutide induced an equal, clinically significant weight loss of 6% in both groups, indicating that the appetite-reducing effect of liraglutide is preserved in MC4R causal obesity and that liraglutide acts independently of the MC4R pathway. Thus, liraglutide could be an effective treatment of the most common form of monogenic obesity.

U2 - 10.1016/j.cmet.2018.05.008

DO - 10.1016/j.cmet.2018.05.008

M3 - Journal article

C2 - 29861388

VL - 28

SP - 23-32.e3

JO - Cell Metabolism

JF - Cell Metabolism

SN - 1550-4131

IS - 1

ER -

ID: 209359841